Boards of directors

Tim Mills, Ph.D., Sanderling Ventures, Taligen Chairman:
 Dr. Mills, Taligen’s chairman, is a managing director of Sanderling Ventures. He has served as the vice president of business development and chief scientific officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific for $1.2 billion in 1997. He also served as a director for Prograft Medical, a Target Therapeutics affiliate. Prior to joining Target Therapeutics, Dr. Mills served as director of business development and advanced research & development in the Interventional Cardiology Division of Baxter Healthcare. Dr. Mills received his Ph.D. in bioengineering from the University of California, Berkeley, and San Francisco School of Medicine, his M.S. in electrical engineering and computer Science from the University of California, Berkeley, and his B.S. in electrical engineering from the University of Colorado, Boulder.

Ed Hurwitz, Alta Partners: Mr. Hurwitz is a director in Alta’s BioPharma III and Alta Partners VIII funds. Prior to joining the firm, he served as senior vice president and CFO of Affymetrix. Before this, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens & Co. and Smith Barney Shearson. He has also practiced commercial law with Cooley Godward LLP. Mr. Hurwitz earned a J.D. and M.B.A. from the University of California, Berkeley’s Boalt School of Law and Haas School of Business, respectively, and a B.A. in molecular biology from Cornell University.

Nick Galakatos, Ph.D., Clarus Ventures: Dr. Galakatos is a co-founder and managing director of Clarus Ventures. He has more than 21 years of industry and investment experience in the healthcare sector, including work in his role as a former general partner of MPM Capital. In addition, Dr. Galakatos has served as vice president of new business with Millennium Pharmaceuticals and in leadership positions with Venrock Associates and Novartis (formerly Ciba), where he was head of molecular biology research. Dr. Galakatos was a co-founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was also chairman. He holds a Ph.D. in organic chemistry from MIT, and completed postdoctoral studies in molecular biology at Harvard Medical School.

Abbie Celniker, Ph.D., Chief Executive Officer, Taligen